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Abstract
Background: Childhood allergic diseases have a major impact on a child’s quality of life, as well as that of their
parents. We studied the coexistence of reported allergies in children who use asthma medication. Additionally, we
tested the hypothesis that asthma severity is greater among children with certain combinations of co-morbid
allergic conditions.
Methods: For this cross-sectional study, 703 children (ages 4 to 12 years) from the PACMAN cohort study were
selected. All of the children were regular users of asthma medication. The study population was divided into nine
subgroups according to parental-reported allergies of the child (hay fever, eczema, food allergy or combinations of
these). In order to assess whether these subgroups differed clinically, the groups were compared for child
characteristics (age, gender, family history of asthma), asthma exacerbations in the past year (oral corticosteroids
(OCS) use; asthma-related emergency department (ED) visits), asthma control, fractional exhaled nitric oxide level
(FeNO), and antihistaminic usage.
Results: In our study, 79.0 % of the parents reported that their child suffered from at least one atopic condition
(hay fever, food allergy and eczema), and one quarter of the parents (25.6 %) reported that their child suffered from
all three atopic conditions. Having more than one atopic condition was associated with an increased risk of OCS
use (OR = 3.3, 95 % CI = 1.6 – 6.6), ED visits (OR = 2.3, 95 % CI = 1.2 – 4.6) in the past year and inadequate short term
asthma control (OR = 1.9, 95 % CI = 1.3 – 2.8).
Conclusions: Children who use asthma medication often also have other allergic conditions. Parental reported
allergies were associated with a higher risk of more severe asthma (more asthma complaints and more asthma
exacerbations).
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Background
Childhood allergic diseases have a major impact on a
child’s quality of life, as well as that of their parents [1].
Therefore, it is important to have a better understanding
of the risk factors associated with the development of
asthma in children, as well as the factors associated with
more severe asthma. The term “allergy” refers to a
hypersensitivity reaction initiated by immunologic mech-
anisms, and although all people are continuously ex-
posed to different allergens, only a limited group of
individuals experience adverse immunologic mecha-
nisms [2]. Persistent asthma is often treated with inhaled
corticosteroids (ICS) in combination with short acting
beta agonists (SABA) as needed, or sometimes in more
severe cases, long acting beta agonists and/or leukotri-
ene antagonists [3]. When asthma is controlled, there
should only be occasional recurrence of symptoms, and
severe asthma exacerbations should be rare [4]. One of
the risk factors for asthma severity that has been
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identified is atopy [5, 6]. Atopic individuals are prone to
developing allergic symptoms. Asthma, food allergies,
eczema, and hay fever are common childhood atopic
conditions with an increasing prevalence in the western
world [7].
In general, eczema peaks in the child’s first years of life
as an “entry point” for subsequent allergic disease, and
consequently the prevalence of asthma and allergic rhin-
itis increases over time as sensitization develops [8].
Several studies have investigated the coexistence of
food allergies and asthma, hay fever and asthma, or ec-
zema and asthma [8–11]. However, most of these studies
have only assessed the relationship between two condi-
tions. They did not assess the effect of a combination of
allergies, and they only focused on atopic patients. In
this study, we examined the coexistence of allergies and
the use of allergy related medication in a large cohort of
children who use asthma medication and were recruited
through community pharmacies. As a result of the inclu-
sion of the participants from the community pharma-
cies, this cohort covered the whole spectrum of children
with mild to severe asthma. Furthermore, we assessed
the differences in the measurement of asthma severity




At the time of this analysis, 744 children (ages 4 to 12
years) were included in the ongoing PACMAN (Pharma-
cogenetics of Asthma medication in Children: Medication
with Anti-inflammatory effects) cohort study. Complete
data on allergies was available for 703 children. The chil-
dren were regular users (≥3 prescriptions in the last two
years and ≥ 1 prescription in the last 6 months) of asthma
medications (R03 on the ATC (Anatomical Therapeutic
Chemical) coding system) and were recruited through
community pharmacies in the Netherlands. The children
and their parents were invited to their regular pharmacy
for a study visit [12]. The design and rationale of the PAC-
MAN study has been described elsewhere [12]. Data
were collected with the help of pharmacists belonging
to the Utrecht Pharmacy Practice Network for Educa-
tion and Research (UPPER), and the work was con-
ducted in compliance with the requirements of the
UPPER institutional review board of the Department
of Pharmacoepidemiology and Clinical Pharmacology,
Utrecht University. The PACMAN study has been ap-
proved by the Medical Ethics Committee of the Uni-
versity Medical Centre Utrecht. Written, informed
consent for all participants in the study was obtained
from either the participants themselves, or, where par-
ticipants were minors, a parent or guardian [12].
Data collection
The parents completed a questionnaire during the phar-
macy visit. The questionnaire contained questions regard-
ing general health, asthma and respiratory symptoms,
allergy symptoms, medication use, adherence to medica-
tion (Medication Adherence Rating Scale (MARS) ques-
tionnaire [13]), socio-demographic factors, and asthma
symptoms. In addition, the child’s fractional exhaled nitric
oxide level (FeNO) was measured with a handheld
analyzer (Niox Mino, Aerocrine, Solna, Sweden).
To measure co-morbid atopic conditions, parents were
asked: Has your child ever had a food allergy (FA) (itch-
ing, rash/hives, vomiting, diarrhea, runny nose, sneezing,
stuffiness and cough)? Has your child ever had eczema?
Has your child ever had hay fever (HF)?
The use of oral corticosteroids (OCS) and the amount
of emergency department (ED) visits were used to meas-
ure asthma severity. Furthermore, the Dutch version of
the 6-item Asthma Control Questionnaire (ACQ) was
applied to assess current asthma control. ACQ ≥ 1.5 was
used as a cut-off value indicating poorly controlled
asthma [14].
Statistical analyses
The study was a cross-sectional analysis in the baseline
measurements of the PACMAN cohort study. The study
population was stratified into nine subgroups according
to the allergies that the parents had reported. The first
three groups reported HF, FA, or eczema irrespective of
whether or not they had also reported one or more of the
other studied allergies. Then all possible combinations of
Fig. 1 The co-existence of allergies in the study population
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Table 1 Characteristics and antihistamines usage
The population
in the Venn diagram a
Number
(Percentage)
Mean Age ± SD Median FeNO
(P Value)b (P Value)c
[IQR]
Study Population 703 8.4 ± 2.4 13.0 [7.0 – 27.0]
Without history of allergies 148 (21.1 %) 8.1 ± 2.4 (.104) 11.0(.084) [6.0 – 27.0]
Eczema 447 (63.6 %) 8.5 ± 2.5 (.485) 13.0 (.222) [8.0 – 26.0]
Food allergy 350 (49.8 %) 8.4 ± 2.5 (.695) 13.0 (.294) [8.0 – 27.0]
Hay fever 309 (44.0 %) 8.9d ± 2.3 (.000) 15.0d (.005) [8.0 – 29.8]
Food allergy + Eczema 283 (40.3 %) 8.5 ± 2.5 (.646) 14.0(.072) [8.3 – 27.8]
Eczema + Hay fever 248 (35.3 %) 8.8d ± 2.4 (.002) 15.0d (.036) [8.5 – 27.5]
Food allergy + Hay fever 200 (28.5 %) 8.7d ± 2.4 (.035) 15.0 (.153) [8.0 – 28.0]
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allergies were defined (FA + eczema, eczema +HF, FA +
HF, FA + eczema +HF) (see Fig. 1 and Table 1).
The characteristics and asthma severity measures of
these groups (age, gender, family history of asthma,
breast feeding, FeNO, use of allergy medications, OSC
usage, ED visits and ACQ) were compared between the
groups of children with and without specific combin-
ation of atopic conditions (colored area in the first col-
umn of Table 1 and the rest of PACMAN population).
We used the independent samples T-test and the Chi-
Square test where appropriate. As the distribution of
FeNO was not normal, according to the Kolomogorov-
Smirnov and the Shapiro-Wilk test, the Mann–Whitney
test was used to compare median FeNO between differ-
ent groups. Logistic regression was applied for multivari-
ate analyses. Age, gender and use of antihistamines were
considered potential confounding factors. The potential
confounding factors were included in the multivariate
model. The Odds Ratios (OR) for OCS use, ED visits
and ACQ were adjusted for age and gender and reported
with 95% confidence intervals CI). Adjusting the OR for
the use of antihistamines and adherence to therapy did
not change the results (Table 4).
Results
Co-existence of allergies
In the study population, 79.0% (555/703) of the parents
reported that their children had suffered from at least
one of the assessed allergies. Eczema was the most com-
mon condition (63.6 %). Almost half of the study popu-
lation reported a history of food allergy (49.8 %), and
hay fever was reported by 44.0 %. 25.6 % (180/703) of
the participants reported symptoms of all three allergies
(food allergy, eczema and hay fever), while 21.1 % did
not report any of these symptoms. (See Fig. 1 and
Table 1).
Baseline characteristics
Characteristics of the study population are shown in
Table 2.
The trends of the main allergic groups’ age distribu-
tions are shown in Fig. 2. For hay fever an ascending
trend is visible (Fig. 2). The mean age of the study popu-
lation was 8.4 years. However, the mean age of the sub-
group of children that reported having hay fever
(irrespective of whether they had other allergies) was sig-
nificantly higher (8.9 years, p < 0.001) (Table 1). Also, the
occurrence of hay fever increased from almost 20 % in
the 4-year-olds to more than 50 % in the 12-year-olds
Table 2 Characteristics of study population
Study population (n = 703)
General characteristics
Male gender, % 62.0
Age, mean ± SD 8.4 ± 2.5
Clinical characteristics
Parental-reported Eczema, % 63.6
Parental-reported Food Allergy, % 49.8
Parental-reported Hay fever, % 44.0
Asthma family history ( One or more parents
with history of asthma), %
48.0
Antihistamine usage, % 30.6
ICS usage, % 87.8
SABA usage, % 84.8
LABA usage, % 23.5
LTRA usage, % 8.8
Breast fed, % 74.9
Median FeNO (IQR) 13.0 (7.0 – 27.0)
OCS usage in the past year, % 7.0
Asthma-related ED visit in the past year, % 6.3
Table 1 Characteristics and antihistamines usage (Continued)
Food allergy + Eczema + Hay fever 180 (25.6 %) 8.8d ± 2.4 (.035) 15.0 (.099) [9.0 – 27.0]
At least two allergies 371 (52.8 %) 8.6 ± 2.4 (.109) 14.0d (.029) [8.0 – 28.0]
aFor a larger diagram see Fig. 1
bWith independent samples T-test
cWith Mann–Whitney test
dP Value < 0.05
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(Fig. 2). The frequency of children with a positive
asthma family history (father or mother) in the total
studied PACMAN population was 48.0 %. In the sub-
group of children who reported having had hay fever,
there was an even higher risk of a family history of
asthma (55 %) compared to the children who did not
report having had hay fever (45.0 %) (OR = 1.7 95 %
CI = 1.2 – 2.3). Furthermore, in the subgroup of chil-
dren with a reported food allergy, there was a trend
towards a higher risk of a family history of asthma
(51.2 % to 48.8 %, OR = 1.3 95 % CI = 1.0 - 1.8)
(Table 3). The median of FeNO in the study popula-
tion was 13.0 (Interquartile Range (IQR) = 7.0 – 27.0).
The children who reported having had hay fever had
a significantly higher FeNO (median = 15.0, IQR = 8.0 –
29.8, p < 0.01) (Table 1). Gender or having been breastfed
did not significantly differ between allergic subgroups.
Oral antihistaminic drug usage
Oral antihistaminic drugs were used by almost 30 % of
the study population. The top three oral antihistaminic
drugs (Loratadine, Cetirizine and Fenistil) were equally
distributed among all the allergy subgroups.
Asthma outcomes
Severity of asthma was assessed by OCS usage, ED visits
and ACQ using both univariate and multivariate ana-
lyses. 9.1 % of the children who reported eczema symp-
toms used OCS (Table 4). This was significantly higher
when compared to the use of OCS in the non-eczema
population (3.2 %) (OR = 3.0, 95 % CI = 1.4 – 6.6). The
use of OCS for the subgroup that had symptoms of food
allergy was 9.6 %; this was also statistically significantly
different compared to 4.3 % of the non-food allergy
population (OR = 2.3, 95 % CI = 1.2 – 4.4). There was a
Fig. 2 The age frequencies of allergic groups in the study population
Table 3 Differences in asthma family history in the allergic subgroups
Asthma family history % (P Value) Odds Ratio
(95 % CI)Group Present Not present
Study population 48.0
Without history of allergies 44.0 (.230) 56.0 0.8 (0.5 – 1.2)
Eczema 48.5 (.741) 51.5 1.1 (0.8 – 1.4)
Food allergy 51.2 (.096) 48.8 1.3 (1.0 - 1.8)
Hay fever 55.0a (.001) 45.0 1.7a (1.2 – 2.3)
Food allergy + Eczema 51.5 (.137) 48.5 1.3 (0.9 – 1.7)
Eczema + Hay fever 54.8a (.009) 45.2 1.5a (1.1 – 2.1)
Food allergy + Hay fever 57.7a (.001) 42.3 1.7a (1.2 – 2.4)
Food allergy + Eczema + Hay fever 57.5a (.004) 42.5 1.7a (1.2 – 2.4)
At least two allergies 51.3 (.070) 48.7 1.3 (1.0 – 1.8)
aP Value < 0.05 with chi-square test
Arabkhazaeli et al. BMC Pediatrics  (2015) 15:172 Page 5 of 9






















OR OR OR OR OR OR
(95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
Study population 7.0 6.3 18.2
Without history of allergies 4.1 (0.12) 0.5 (0.2–1.2) 0.5 (0.2–1.2) 4.1 (.215) 0.6 (0.2–1.4) 0.5 (0.2–1.3) 14.3 (.118) 0.7 (0.4–1.1) 0.7 (0.4–1.1)
Eczema 9.1a (.003) 3.0a (1.4–6.6) 3.0a (1.4–6.6) 8.1a (.010) 2.7a (1.2–5.9) 2.7a (1.2–6.0) 20.4 (.053) 1.5 (1.0–2.3) 1.5a (1.0–2.4)
Food allergy 9.6a (.007) 2.3a (1.2–4.4) 2.3a (1.2–4.4) 8.0 (.068) 1.8 (1.0–3.4) 1.8 (0.9–3.4) 21.3a (.039) 1.5a (1.0–2.2) 1.5a (1.0–2.2)
Hay fever 8.0 (0.36) 1.3 (0.7–2.4) 1.4 (0.8–2.5) 6.0 (.765) 0.9 (0.5–1.7) 1.1 (0.6–2.1) 22.7a (.007) 1.7a (1.2–2.5) 1.8a (1.2–2.7)
Food allergy + Eczema 11.6a (.000) 3.2a (1.7–6.0) 3.3a (1.8–6.1) 9.6a (.005) 2.4a (1.3–4.6) 2.5a (1.3–4.7) 22.1a (.028) 1.5a (1.0–2.3) 1.6a (1.1–2.3)
Eczema + Hay fever 9.5 (.056) 1.8 (1.0–3.2) 1.8a (1.0–3.3) 7.1 (.557) 1.2 (0.6–2.3) 1.4 (0.7–2.7) 24.5a (.002) 1.9a (1.3–2.8) 1.9a (1.3–2.9)
Food allergy + Hay fever 9.2 (0.14) 1.6 (0.9–2.9) 1.6 (0.9–3.0) 6.7 (.776) 1.1 (0.6–2.2) 1.2 (0.6–2.5) 25.4a (.002) 1.9a (1.3–2.8) 1.9a (1.3–2.9)
Food allergy + Eczema +
Hay fever
10.3a (.045) 1.9a (1.0–3.4) 1.9 (1.0–3.6) 7.5 (.467) 1.3 (0.7–2.5) 1.5 (0.7–2.9) 25.3a (.005) 1.8a (1.2–2.7) 1.9a (1.2–2.8)
At least two allergies 10.1a (.001) 3.2a (1.6–6.4) 3.3a (1.6–6.6) 8.4a (.020) 2.2a (1.1–4.3) 2.3a (1.2–4.6) 22.4a (.003) 1.9a (1.2-2.8) 1.9a (1.3–2.8)
The referent group for all these odds ratios is the entire study population
aP Value < 0.05 with logistic regression test











trend towards a higher risk for the use of OCS in all al-
lergy subgroups. However, the group of children who
did not report a history of allergic conditions did not
have an increased risk for the use of OCS (Table 4).
Emergency department visits during the past year were
significantly higher (8.1 %, OR = 2.7, 95 % CI = 1.2 – 6.0)
in the population who had a history of eczema as com-
pared to the rest of the population (3.2 %) (Table 4).
The Asthma Control Questionnaire (ACQ) was assessed
in all the defined groups, and 18.2 % of the total study
population suffered from poorly controlled asthma. The
frequencies of poorly controlled asthmatics in all allergic
subgroups were significantly higher (p < 0.05) as compared
to the non-allergic population. They were 21.3 %, 20.4 %
and 22.1 % in the populations with a history of eczema,
food allergy or both, respectively. The frequencies of
poorly controlled patients were even higher in all the sub-
groups that reported hay fever (22.7 % - 25.4 %) or more
than one allergy (22.4 %) compared to the rest of study
population (Table 4).
Discussion
In this large pharmacy-based study of children with a re-
ported use of asthma medication, we found that the
prevalence of children that reported symptoms of one or
more allergy syndromes was high, and patients that re-
ported more atopic conditions had a greater odds of
more severe asthma.
In general, children with asthma and co-morbid aller-
gic conditions were more often poorly controlled com-
pared to their non-allergic peers. Furthermore, usage of
OCS and asthma-related ED visits were more common
in children who reported more than one atopic condi-
tion, which was approximately half of the study popula-
tion. This indicates that the presence of a more
complicated allergic phenotype significantly influences
the severity of asthma [15].
To our knowledge, there is limited research that has
studied the association of allergic comorbidities and
asthma severity [16]. However several longitudinal stud-
ies have shown that approximately half of eczema pa-
tients will develop asthma, particularly patients with
severe eczema [8]. A study by Roberts et al. showed that
children with food allergies are around 6 times more
likely to suffer from severe asthma later in life than chil-
dren who did not have food allergies. Similarly, Priftis et
al. showed that approximately 40 % of children who
were diagnosed with an egg and/or fish allergy in the
first three years of their life reported current asthma
symptoms at school age [17, 18]. Moreover, hay fever
has been described as a major risk factor for asthma
[19, 20]. In the current study, eczema was the most
frequently reported allergy among the three allergies
(food allergy, eczema and hay fever), reported by 63 % of
the population (Table 2). A remarkably high percentage of
the parents (25.6 %) reported that their children had expe-
rienced all three allergies (Fig. 1). The prevalence of food
allergy in the current study was also very high (49.8 %).
Earlier studies showed that the prevalence of food allergy
varied between 3 % and 35 % [7]. Likewise a Dutch study
reported a prevalence of (current) self-reported food al-
lergy around 7.2 % among school children in the
Netherlands [21]. The high prevalence in our study may
have been influenced by the fact that we asked whether
the child had ever experienced symptoms. Some children
might have only experienced symptoms in early child-
hood, and this may have caused a larger prevalence than
the prevalence of current food allergy symptoms. Never-
theless, we do realize that self-reporting might lead to an
overestimation. Unfortunately, data regarding provocation
testing to confirm an actual diagnosis of food allergy were
not available. However, it has been shown that results
from screening questionnaires, comparable to the one we
used in this study, were in concordance with results from
specific IgE measurements and information obtained from
patient records [22, 23].
When we assessed the effect of age on the develop-
ment of allergic disease, we noticed that the occurrence
of hay fever increased with age in our study population
(Fig. 2). Moreover, the mean age of the hay fever group
(8.9 ± 2.5) was significantly higher than the mean age in
the overall study population (Table 2). The same trend
was reported by Spergel et al. where the incidence of
hay fever increased over time during childhood. This
might be caused by sensitization developed through
other allergic conditions [8]. Ghouri et al. showed an in-
crease in the prevalence of hay fever during childhood in
England as well [24]. On the other hand, age trends in
the occurrence of the eczema were not observed. Spergel
et al. reported age incidence of eczema peaks in the first
years of life [8]. It might, therefore, be that our popula-
tion was too old to observe this trend. The median
FeNO level was significantly higher in the hay fever
group. This is in alignment with other studies that con-
firm high FeNO levels in hay fever sufferers [25, 26].
Our study was limited by the lack of physicians’ diag-
noses on allergic diseases or objective immunological
test results. We used a questionnaire to obtain informa-
tion about the history of allergic conditions. Other stud-
ies (such as ISAAC [27]) have also used questionnaire
data. We realize, however, that this questionnaire data
might differ from objective tests, and the occurrence of
allergic diseases might therefore have been overesti-
mated due to the use of parental-reported data. How-
ever, the strength of our study is in the selection of a
large set of asthmatic children through community
pharmacies. Our population represents a cross-section
of the everyday pediatric asthma population that
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varies in the severity of the disease, health care
utilization and asthma control.
Conclusions
In conclusion, our study suggests that children with
asthma and co-morbid atopic conditions are at risk for
more exacerbations and less well-controlled asthma in
comparison to children who did not report allergies. The
children who were reported to have had more than one
allergic co-morbidity were especially at risk of having
less well controlled asthma and more severe exacerba-
tions. This may have clinical implications, such as
more unscheduled health care visits and hospitaliza-
tions, as these patients may experience more severe
asthma. These children should be carefully monitored
and might benefit from asthma/allergy specialist care
at an earlier stage.
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